Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

Completed · Phase 2

Conditions studied: Fabry Disease

In brief

The objective was to determine the effects of a single dose of migalastat hydrochloride (HCl) (migalastat) 150 and 450 milligrams (mg) on the safety and plasma pharmacokinetics (PK) of agalsidase and the effects of agalsidase on the safety and PK of migalastat 150 mg.

Key facts

Study ID

NCT01196871

Run by

Amicus Therapeutics

People needed

20

Starts

2011-02-02

Expected to finish

2012-10-09

Last updated by the study team

2018-12-19

Who can join

Age: 18 and older, up to 65. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Male diagnosed with Fabry disease and between 18 and 65 years of age, inclusive
• Body mass index between 18-35 kg per meter squared
• Had initiated treatment with agalsidase at least 1 month prior to screening, and had received at least 2 infusions before screening
• Had stable dose level, dosing regimen, and form of agalsidase for at least 1 month before screening
• Had an estimated creatinine clearance greater than or equal to 50 milliliters (mL)/minute at screening
• Agreed to use medically accepted methods of contraception during the study and for 30 days after study completion
• Were willing and able to provide written informed consent

You may not qualify if…

• Had a documented transient ischemic attack, ischemic stroke, unstable angina, or myocardial infarction within the 3 months before screening
• Had clinically significant unstable cardiac disease (for example, cardiac disease requiring active management, such as symptomatic arrhythmia, unstable angina, or New York Heart Association class III or IV congestive heart failure)
• History of allergy or sensitivity to study drug (including excipients) or other iminosugars (such as miglustat, miglitol)
• Required a concomitant medication prohibited by the protocol: Glyset® (miglitol), or Zavesca® (miglustat)
• Any investigational/experimental drug or device within 30 days of screening, except for use of investigational enzyme replacement therapy for Fabry disease
• Had any intercurrent illness or condition that might have precluded the participant from fulfilling the protocol requirements or suggested to the investigator that the potential participant might have had an unacceptable risk by participating in this study

Where it is running

• Study site — Birmingham, Alabama, United States
• Study site — Decatur, Georgia, United States
• Study site — Iowa City, Iowa, United States
• Study site — Kansas City, Kansas, United States
• Study site — Springfield, Virginia, United States
• Study site — Nedlands, Australia
• Study site — Parkville, Australia
• Study site — Edegem, Belgium
• Study site — Montreal, Canada
• Study site — Amsterdam, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.